{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T15:48:32Z","timestamp":1764604112250,"version":"3.40.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["CEECINST\/00049\/2021\/CP2817\/CT0001"],"award-info":[{"award-number":["CEECINST\/00049\/2021\/CP2817\/CT0001"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-10866-x","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:24:51Z","timestamp":1745425491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long term bivalent mRNA vaccine effectiveness against COVID-19 hospitalisations and deaths in Portugal: a cohort study based on electronic health records"],"prefix":"10.1186","volume":"25","author":[{"given":"Ausenda","family":"Machado","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Kislaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Soares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baltazar","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"On behalf of PT-EHR vaccine group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Paula","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Pinto","family":"Leite","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Matias","family":"Dias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"10866_CR1","unstructured":"Dire\u00e7\u00e3o Geral da Sa\u00fade. Norma no 008\/2022 de 02\/09\/2022 atualizada 06\/09\/2022 - Campanha de vacina\u00e7\u00e3o sazonal contra a COVID-19: OutonoInverno 2022\u20132023. 2022;:3."},{"key":"10866_CR2","unstructured":"Dire\u00e7\u00e3o Geral da Sa\u00fade. Norma no 009\/2022 de 06\/09\/2022 Vacina Comirnaty Original\/Omicron BA.1\u00ae. 2022;:3."},{"key":"10866_CR3","unstructured":"Dire\u00e7\u00e3o Geral da Sa\u00fade. Norma no 010\/2022 de 20\/09\/2022 Vacina\u00e7\u00e3o contra a COVID-19: Vacina Comirnaty Original\/Omicron BA.4\u20135\u00ae. 2022."},{"key":"10866_CR4","unstructured":"Dire\u00e7\u00e3o Geral da Sa\u00fade. Norma no 011\/2022 de 21\/09\/2022 vacina\u00e7\u00e3o contra a COVID-19. Vacina Spikevax Bivalente Original\/Omicron BA.1\u00ae; 2022."},{"key":"10866_CR5","unstructured":"European Centre for Disease Prevention and Control. COVID-19 Vaccine Tracker. 2023. https:\/\/vaccinetracker.ecdc.europa.eu\/public\/extensions\/COVID-19\/vaccine-tracker.html#national-ref-tab. Accessed 31 Aug 2023."},{"key":"10866_CR6","unstructured":"Dire\u00e7\u00e3o Geral da Sa\u00fade. Norma no 002\/2021 de 30\/01\/2021 atualizada 02\/09\/2022. 2022."},{"key":"10866_CR7","unstructured":"Instituto Nacional de Sa\u00fade Doutor Ricardo Jorge. Genetic diversity of the novel coronavirus SARS-CoV-2 (COVID-19) in Portugal. 2023. https:\/\/insaflu.insa.pt\/covid19\/. Accessed 31 Jul 2023."},{"key":"10866_CR8","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1038\/s41467-023-38435-3","volume":"14","author":"T Tamura","year":"2023","unstructured":"Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Anraku Y, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun. 2023;14:2800.","journal-title":"Nat Commun"},{"key":"10866_CR9","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1473-3099(23)00122-6","volume":"23","author":"R Arbel","year":"2023","unstructured":"Arbel R, Peretz A, Sergienko R, Friger M, Beckenstein T, Duskin-Bitan H, et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study. Lancet Infect Dis. 2023;23:914\u201321.","journal-title":"Lancet Infect Dis"},{"key":"10866_CR10","first-page":"1","volume":"July","author":"M Stecher","year":"2023","unstructured":"Stecher M, Kristoffersen AB, Lie K, Andersen SR, Meijerink H, Starrfelt J. Effectiveness and durability of a second COVID-19 booster against severe outcomes among older people in Norway: a population-based cohort study comparing mono- and bivalent booster doses. Int J Epidemiol. 2023;July:1\u20139.","journal-title":"Int J Epidemiol"},{"key":"10866_CR11","first-page":"1","volume":"3099","author":"FCM Kirsebom","year":"2023","unstructured":"Kirsebom FCM, Andrews N, Stowe J, Ramsay M, Lopez Bernal J. Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study. Lancet Infect Dis. 2023;3099:1\u20139.","journal-title":"Lancet Infect Dis"},{"key":"10866_CR12","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin DR, Higdon MM, Abu-Raddad LJ, Andrews N, Araos R, Goldberg Y, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022;399:924\u201344.","journal-title":"Lancet"},{"key":"10866_CR13","doi-asserted-by":"publisher","first-page":"e0274008","DOI":"10.1371\/journal.pone.0274008","volume":"17","author":"A Machado","year":"2022","unstructured":"Machado A, Kislaya I, Rodrigues AP, Sequeira D, Lima J, Cruz C, et al. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged\u2009\u2265\u200965 years in Portugal: A cohort study based on data-linkage of National registries February-September 2021. PLoS ONE. 2022;17:e0274008.","journal-title":"PLoS ONE"},{"key":"10866_CR14","doi-asserted-by":"crossref","unstructured":"Kislaya I, Machado A, Magalh\u00e3es S, Rodrigues AP, Franco R, Leite PP et al. COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022. Eurosurveillance. 2022;27.","DOI":"10.2807\/1560-7917.ES.2022.27.37.2200697"},{"key":"10866_CR15","doi-asserted-by":"crossref","unstructured":"Nunes B, Rodrigues AP, Kislaya I, Cruz C, Peralta-Santos A, Lima J et al. mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of National health registries in Portugal, February to August 2021. Eurosurveillance. 2021;26.","DOI":"10.2807\/1560-7917.ES.2021.26.38.2100833"},{"key":"10866_CR16","doi-asserted-by":"publisher","first-page":"e075286","DOI":"10.1136\/bmj-2022-075286","volume":"382","author":"NW Andersson","year":"2023","unstructured":"Andersson NW, Thiesson EM, Baum U, Pihlstr\u00f6m N, Starrfelt J, Faksov\u00e1 K, et al. Comparative effectiveness of bivalent BA.4\u20135 and BA.1 mRNA booster vaccines among adults aged\u2009\u2265\u200950 years in nordic countries: nationwide cohort study. BMJ. 2023;382:e075286.","journal-title":"BMJ"},{"key":"10866_CR17","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1016\/j.vaccine.2024.04.049","volume":"42","author":"S Song","year":"2024","unstructured":"Song S, Madewell ZJ, Liu M, Miao Y, Xiang S, Huo Y, et al. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants. Vaccine. 2024;42:3389\u201396.","journal-title":"Vaccine"},{"key":"10866_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2807\/1560-7917.ES.2023.28.32.2300397","volume":"28","author":"M Fabiani","year":"2023","unstructured":"Fabiani M, Mateo-Urdiales A, Sacco C, Rota MC, Fotakis EA, Petrone D, et al. Relative effectiveness of bivalent Original\/Omicron BA.4\u20135 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023. Euro Surveill. 2023;28:1\u20137.","journal-title":"Euro Surveill"},{"key":"10866_CR19","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1056\/NEJMc2302462","volume":"388","author":"D-Y Lin","year":"2023","unstructured":"Lin D-Y, Xu Y, Gu Y, Zeng D, Sunny SK, Moore Z. Durability of bivalent boosters against Omicron subvariants. N Engl J Med. 2023;388:1818\u201320.","journal-title":"N Engl J Med"},{"key":"10866_CR20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/s43587-022-00292-y","volume":"2","author":"M\u00c1 Palacios-Pedrero","year":"2022","unstructured":"Palacios-Pedrero M\u00c1, Jansen JM, Blume C, Stanislawski N, Jonczyk R, Molle A, et al. Signs of Immunosenescence correlate with poor outcome of mRNA COVID-19 vaccination in older adults. Nat Aging. 2022;2:896\u2013905.","journal-title":"Nat Aging"},{"key":"10866_CR21","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0140-6736(22)02465-5","volume":"401","author":"C Stein","year":"2023","unstructured":"Stein C, Nassereldine H, Sorensen RJD, Amlag JO, Bisignano C, Byrne S, et al. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023;401:833\u201342.","journal-title":"Lancet"},{"key":"10866_CR22","unstructured":"Dire\u00e7\u00e3o Geral da Sa\u00fade. Norma no013\/2022 de 28.11.2022 -Abordagem das Pessoas com suspeita ou confirma\u00e7\u00e3o de COVID-19. 2022;:20."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10866-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10866-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10866-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T16:25:00Z","timestamp":1745425500000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10866-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10866"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10866-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"26 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Ethical Committee and the Data Protection Officer of the National Institute of Health Doutor Ricardo Jorge (December 13, 2022), the need for the participants\u2019 informed consent was waived by the Ethical Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"590"}}